6.83
-1.21 (-15.05%)
| Penutupan Terdahulu | 8.04 |
| Buka | 7.85 |
| Jumlah Dagangan | 328,686 |
| Purata Dagangan (3B) | 657,316 |
| Modal Pasaran | 371,601,856 |
| Harga / Buku (P/B) | 1.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Mar 2025 |
| EPS Cair (TTM) | -10.38 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.81% |
| Nisbah Semasa (MRQ) | 6.01 |
| Aliran Tunai Operasi (OCF TTM) | -255.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -150.41 M |
| Pulangan Atas Aset (ROA TTM) | -87.31% |
| Pulangan Atas Ekuiti (ROE TTM) | -198.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Alumis Inc. | Menurun | - |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.38 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.21% |
| % Dimiliki oleh Institusi | 85.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 31 Dec 2024 | 10,645,966 |
| Foresite Capital Management V, Llc | 31 Dec 2024 | 5,779,348 |
| Venbio Partners Llc | 31 Dec 2024 | 2,787,398 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 32.00 (Oppenheimer, 368.52%) | Beli |
| Median | 23.00 (236.75%) | |
| Rendah | 14.00 (HC Wainwright & Co., 104.98%) | Beli |
| Purata | 23.00 (236.75%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 5.85 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Apr 2025 | 14.00 (104.98%) | Beli | 4.97 |
| 26 Mar 2025 | 15.00 (119.62%) | Beli | 4.92 | |
| Oppenheimer | 30 Jan 2025 | 32.00 (368.52%) | Beli | 6.72 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |